Apple has once again triumphed in a high-stakes patent battle, securing a crucial win against AliveCor in a fight that could have led to an import ban on the Apple Watch. The U.S. Court of Appeals for the Federal Circuit today upheld the invalidation of AliveCor’s patents, closing a chapter in a years-long legal saga that has pitted the Cupertino giant against a smaller medical tech company claiming Apple unfairly leveraged its innovations.
Federal Court Sides with Apple, Invalidating AliveCor’s ECG Patents
The dispute dates back to 2020, when AliveCor accused Apple of infringing its patents related to ECG technology, which was integrated into the Apple Watch starting with the Series 4. AliveCor, best known for its KardiaBand accessory that brought FDA-cleared electrocardiogram capabilities to the Apple Watch before Apple introduced its own version, claimed the tech giant copied its innovations while simultaneously blocking third-party developers like AliveCor from operating freely on its platform. The company sought an import ban at the U.S. International Trade Commission (ITC), which initially ruled in AliveCor’s favor, determining that Apple had indeed infringed its patents.
But Apple wasn’t going down without a fight. The company took the matter to the U.S. Patent and Trademark Office’s Patent Trial and Appeal Board (PTAB), which ultimately ruled in Apple’s favor, stating that AliveCor’s patents were unpatentable due to prior art. That decision weakened AliveCor’s case, and today’s ruling from the Federal Circuit cements the outcome: AliveCor’s patents won’t stand, and there will be no Apple Watch import ban.
AliveCor, unsurprisingly, isn’t happy. The company expressed disappointment over the decision, stating that it threatens smaller innovators by allowing corporate giants to dominate the industry unchecked. But for Apple, this is yet another victory in its battle to maintain the Apple Watch’s position as the go-to wearable for health tracking. Meanwhile, a separate Apple Watch import ban over Masimo’s blood oxygen technology remains in effect—at least for now.
For more daily updates, please visit our News Section.
Stay ahead in tech! Join our Telegram community and sign up for our daily newsletter of top stories! 💡
Comments